LIPC-AS1: A Potential Drug Target and Biomarker (G101928694)

Target Name: LIPC-AS1

NCBI ID: G101928694

LIPC-AS1

Other Name(s): LIPC antisense RNA 1

LIPC-AS1: A Potential Drug Target and Biomarker

LIPC-AS1 (LIPC-alpha-1), also known as LIPC-AS1-containing RNA, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. LIPC-AS1 is derived from the last exon of the long non-coding RNA LIPC-alpha-1 (LIPC-AS1), which is located on the X chromosome.

The LIPC-AS1 molecule has unique properties that make it an attractive drug target. Firstly, LIPC-AS1 is highly stable and has a long half-life of approximately 24 hours, which allows for efficient delivery to the endoplasmic system and persistent expression in the cells. Secondly, LIPC-AS1 is highly resistant to degradation, which allows for sustained expression in the cells. Lastly, LIPC-AS1 is a good predictor of gene expression, which can be used to identify potential drug targets.

In addition to its potential as a drug target, LIPC-AS1 has also been identified as a potential biomarker. The expression of LIPC-AS1 has been shown to be downregulated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Additionally, LIPC-AS1 has been shown to play a role in disease progression by promoting the progression of cancer cells and increasing the sensitivity of cancer cells to chemotherapy.

The discovery of LIPC-AS1 as a potential drug target and biomarker has important implications for the development of new treatments for various diseases. For example, LIPC-AS1 could be used as a target for small molecule inhibitors, which would reduce the production of LIPC-AS1 and decrease the level of disease-promoting activity. Additionally, LIPC-AS1 could be used as a biomarker for monitoring disease progression and responding to treatment.

In conclusion, LIPC-AS1 is a promising drug target and biomarker that has the potential to revolutionize the development of new treatments for various diseases. Further research is needed to fully understand the role of LIPC-AS1 in disease progression and to develop effective inhibitors of LIPC-AS1.

Protein Name: LIPC Antisense RNA 1

The "LIPC-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIPC-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets